Yaoming Kant's daily limit today, the stock has been in the 13th consecutive days (including 44%increase on the first day). As of the press release, the stock has not opened the daily limit, and it is reported at 97.60 yuan. As the first "unicorn" that can only be played, after the 13th daily limit board of E -Kant to seal after the listing, according to the issuance price of 21.6 yuan, the profit of one of the signed one has reached 76,000 yuan, refreshing the previous Yoshwo Wo Wowo. Ge Optoelectronics has made the most profitable new stock records in the year. After the new shares were listed, 8 consecutive one -fledged boards were calculated at the average price of the opening daily. It has become one of the "four giants" of the 100 billion market value after Hengrui Pharmaceutical , Yunnan Baiyao, and Kangmei Pharmaceutical.
public information shows that Yin Ming Kant is currently the largest small molecular pharmaceutical R & D service enterprise in China and is the leader of the CRO (pharmaceutical research and development contract outsourcing service agency) industry. In 2007, Yao Kanto was listed on the New York Stock Exchange , with a market value of more than 3 billion US dollars. In August 2015, he announced privatization. He delisted from the NYSE on December 10 of that year and set foot on the journey to return to A shares. After the delisting of US stocks, Yaoming Kant was split into the three major categories of businesses to listed separately: He Quan Pharmaceutical landed in the New Third Board in April 2015; Yaoming creatures listed in Hong Kong in June 2017; coupled with A shares medicines of A shares, the medicines of A shares Ming Kangde. At present, the market value of Hequan Pharmaceuticals is 20 billion (as of May 24), the value of Yaoming Biological Harbor is 80 billion (as of May 24), and the market value of Yaoming Kant is 101.7 billion (as of May 24). The market value has exceeded 200 billion. From the delisting of U.S. stocks to now, the market value has twice more than two years. The prospectus of
shows that Yao Ming Kangde is currently not controlled by the controlling shareholder. Li Ge , Zhao Ning, Liu Xiaozhong, and Zhang Zhaohui four founders were unanimously controlled by 34.48%of the company's voting rights.
Li Ge and Zhao Ning are husband and wife of Peking University. With the listing of Yao Ming Kant, the couple's net worth has increased. As of May 9th, through indirect holdings, the market value of Li Ge and Zhao Ning's three companies in Yaoming Kangde, Hequan Pharmaceutical, and Yaoming Bio was 25.77 billion yuan, 13.441 billion yuan, and 51193 billion yuan, respectively. It reached 90.404 billion yuan ($ 14.153 billion). It is worth mentioning that
is worth mentioning that the prospectus disclosed that Yaoming Kangde originally plans to issue 104 million shares, raising 5.741 billion yuan, and calculated about 55.20 yuan/share. The final issuance results show that its starting price is set at 21.60 yuan/share, and the number of issuance remains unchanged, and the amount of fundraising has shrunk by 60%to 2.246 billion yuan. At the same time that the amount of
Yaoming Kangde's fundraising amount decreased, the issuance price -earnings ratio also dropped to about 22.99 times, and the issue price -earnings ratio of the distribution of less than 23 times determined a benchmark for the launch of the subsequent "unicorn" enterprises. Industry insiders said that much lower than the industry P / E ratio , leaving plenty of room for the secondary market.
Daily Economic News Integrity from Sina Finance, Zhongxin Jingwei, every APP
Daily Economic News
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-